Table 3.
The design and synthesis of dihydropyran-fused oridonin derivatives as potential anticancer agents.
| |||||
|---|---|---|---|---|---|
| Compd | R | EC50 (μM)
|
|||
| MCF-7 | MDA-MB-231 | MDA-MB-468 | MCF-7/ADR | ||
| 1 | - | 4.4 | 28.0 | 5.3 | 34.8 |
| Adriamycin | - | 0.7 | 2.3 | 0.7 | > 10 |
| 32 |
|
2.4 | 3.7 | 5.8 | 6.8 |
| 33 |
|
0.44 | 0.54 | 0.52 | 1.6 |
| 34 |
|
5.8 | 8.2 | 7.0 | 10.3 |
| 35 |
|
2.1 | 3.3 | 4.4 | 3.2 |
| 36 |
|
6.8 | 7.2 | 7.3 | 8.7 |
| 37 |
|
2.4 | 2.2 | 3.0 | 3.8 |
| 38 |
|
3.5 | 6.1 | 5.4 | 4.7 |
| 39 |
|
2.2 | 1.8 | 2.6 | 4.4 |
| 40 |
|
4.3 | 7.1 | 4.9 | 4.3 |
| 41 |
|
2.3 | 3.3 | 3.0 | 3.1 |